Efficacy of Neoadjuvant Chemotherapy DOX and XELOX Regimens for Patients with Resectable Gastric or Gastroesophageal Junction Adenocarcinoma
Purpose. This paper is aimed at comparing the short-term efficacy of the combination of docetaxel, oxaliplatin, and capecitabine (DOX) with the combination of oxaliplatin and capecitabine (XELOX) as neoadjuvant chemotherapy regimens for the treatment of patients with resectable gastric or gastroesop...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-01-01
|
| Series: | Gastroenterology Research and Practice |
| Online Access: | http://dx.doi.org/10.1155/2021/5590626 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832561348624515072 |
|---|---|
| author | Yuan Tian Qun Zhao Yong Li Liqiao Fan Zhidong Zhang Xuefeng Zhao Bibo Tan Dong Wang Peigang Yang |
| author_facet | Yuan Tian Qun Zhao Yong Li Liqiao Fan Zhidong Zhang Xuefeng Zhao Bibo Tan Dong Wang Peigang Yang |
| author_sort | Yuan Tian |
| collection | DOAJ |
| description | Purpose. This paper is aimed at comparing the short-term efficacy of the combination of docetaxel, oxaliplatin, and capecitabine (DOX) with the combination of oxaliplatin and capecitabine (XELOX) as neoadjuvant chemotherapy regimens for the treatment of patients with resectable gastric or gastroesophageal junction adenocarcinoma. Methods. A total of 300 patients aged 20-60 years with resectable gastric or gastroesophageal junction adenocarcinoma who were evaluated with cT3/4Nany were randomly assigned into 3 groups: DOX group (n=100, treated with neoadjuvant DOX plus adjuvant XELOX), XELOX group (n=100, treated with perioperative XELOX), and surgery group (n=100, treated with adjuvant XELOX). Results. A total of 93, 92, and 95 patients were enrolled in the DOX, XELOX, and surgery groups, respectively. The pathological complete response (pCR) rate was 16.1% in the DOX group and 4.3% in the XELOX group (P=0.008). There were 56 (61.3%) patients in the DOX group who presented with surgical complications, 22 (23.9%) patients in the XELOX group, and 37 (38.9%) patients in the surgery group. The most common grade 3-4 adverse events in these three groups were neutropenia (32.3%, 30.4%, and 21.1%), leucopenia (21.5%, 22.8%, and 15.8%), nausea (15.1%, 16.3%, and 12.6%), and fatigue (10.8%, 7.6%, and 8.4%). Conclusions. Neoadjuvant DOX is an effective and feasible regimen and might represent an option for young and middle-aged patients with locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma. |
| format | Article |
| id | doaj-art-375f18e4ad2d4ea3ad2d76b29743b864 |
| institution | Kabale University |
| issn | 1687-6121 1687-630X |
| language | English |
| publishDate | 2021-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Gastroenterology Research and Practice |
| spelling | doaj-art-375f18e4ad2d4ea3ad2d76b29743b8642025-02-03T01:25:18ZengWileyGastroenterology Research and Practice1687-61211687-630X2021-01-01202110.1155/2021/55906265590626Efficacy of Neoadjuvant Chemotherapy DOX and XELOX Regimens for Patients with Resectable Gastric or Gastroesophageal Junction AdenocarcinomaYuan Tian0Qun Zhao1Yong Li2Liqiao Fan3Zhidong Zhang4Xuefeng Zhao5Bibo Tan6Dong Wang7Peigang Yang8Department of General Surgery, The Fourth Affiliated Hospital, Hebei Medical University, No.12, Jian-Kang Road, Shijiazhuang 050019, ChinaDepartment of General Surgery, The Fourth Affiliated Hospital, Hebei Medical University, No.12, Jian-Kang Road, Shijiazhuang 050019, ChinaDepartment of General Surgery, The Fourth Affiliated Hospital, Hebei Medical University, No.12, Jian-Kang Road, Shijiazhuang 050019, ChinaDepartment of General Surgery, The Fourth Affiliated Hospital, Hebei Medical University, No.12, Jian-Kang Road, Shijiazhuang 050019, ChinaDepartment of General Surgery, The Fourth Affiliated Hospital, Hebei Medical University, No.12, Jian-Kang Road, Shijiazhuang 050019, ChinaDepartment of General Surgery, The Fourth Affiliated Hospital, Hebei Medical University, No.12, Jian-Kang Road, Shijiazhuang 050019, ChinaDepartment of General Surgery, The Fourth Affiliated Hospital, Hebei Medical University, No.12, Jian-Kang Road, Shijiazhuang 050019, ChinaDepartment of General Surgery, The Fourth Affiliated Hospital, Hebei Medical University, No.12, Jian-Kang Road, Shijiazhuang 050019, ChinaDepartment of General Surgery, The Fourth Affiliated Hospital, Hebei Medical University, No.12, Jian-Kang Road, Shijiazhuang 050019, ChinaPurpose. This paper is aimed at comparing the short-term efficacy of the combination of docetaxel, oxaliplatin, and capecitabine (DOX) with the combination of oxaliplatin and capecitabine (XELOX) as neoadjuvant chemotherapy regimens for the treatment of patients with resectable gastric or gastroesophageal junction adenocarcinoma. Methods. A total of 300 patients aged 20-60 years with resectable gastric or gastroesophageal junction adenocarcinoma who were evaluated with cT3/4Nany were randomly assigned into 3 groups: DOX group (n=100, treated with neoadjuvant DOX plus adjuvant XELOX), XELOX group (n=100, treated with perioperative XELOX), and surgery group (n=100, treated with adjuvant XELOX). Results. A total of 93, 92, and 95 patients were enrolled in the DOX, XELOX, and surgery groups, respectively. The pathological complete response (pCR) rate was 16.1% in the DOX group and 4.3% in the XELOX group (P=0.008). There were 56 (61.3%) patients in the DOX group who presented with surgical complications, 22 (23.9%) patients in the XELOX group, and 37 (38.9%) patients in the surgery group. The most common grade 3-4 adverse events in these three groups were neutropenia (32.3%, 30.4%, and 21.1%), leucopenia (21.5%, 22.8%, and 15.8%), nausea (15.1%, 16.3%, and 12.6%), and fatigue (10.8%, 7.6%, and 8.4%). Conclusions. Neoadjuvant DOX is an effective and feasible regimen and might represent an option for young and middle-aged patients with locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma.http://dx.doi.org/10.1155/2021/5590626 |
| spellingShingle | Yuan Tian Qun Zhao Yong Li Liqiao Fan Zhidong Zhang Xuefeng Zhao Bibo Tan Dong Wang Peigang Yang Efficacy of Neoadjuvant Chemotherapy DOX and XELOX Regimens for Patients with Resectable Gastric or Gastroesophageal Junction Adenocarcinoma Gastroenterology Research and Practice |
| title | Efficacy of Neoadjuvant Chemotherapy DOX and XELOX Regimens for Patients with Resectable Gastric or Gastroesophageal Junction Adenocarcinoma |
| title_full | Efficacy of Neoadjuvant Chemotherapy DOX and XELOX Regimens for Patients with Resectable Gastric or Gastroesophageal Junction Adenocarcinoma |
| title_fullStr | Efficacy of Neoadjuvant Chemotherapy DOX and XELOX Regimens for Patients with Resectable Gastric or Gastroesophageal Junction Adenocarcinoma |
| title_full_unstemmed | Efficacy of Neoadjuvant Chemotherapy DOX and XELOX Regimens for Patients with Resectable Gastric or Gastroesophageal Junction Adenocarcinoma |
| title_short | Efficacy of Neoadjuvant Chemotherapy DOX and XELOX Regimens for Patients with Resectable Gastric or Gastroesophageal Junction Adenocarcinoma |
| title_sort | efficacy of neoadjuvant chemotherapy dox and xelox regimens for patients with resectable gastric or gastroesophageal junction adenocarcinoma |
| url | http://dx.doi.org/10.1155/2021/5590626 |
| work_keys_str_mv | AT yuantian efficacyofneoadjuvantchemotherapydoxandxeloxregimensforpatientswithresectablegastricorgastroesophagealjunctionadenocarcinoma AT qunzhao efficacyofneoadjuvantchemotherapydoxandxeloxregimensforpatientswithresectablegastricorgastroesophagealjunctionadenocarcinoma AT yongli efficacyofneoadjuvantchemotherapydoxandxeloxregimensforpatientswithresectablegastricorgastroesophagealjunctionadenocarcinoma AT liqiaofan efficacyofneoadjuvantchemotherapydoxandxeloxregimensforpatientswithresectablegastricorgastroesophagealjunctionadenocarcinoma AT zhidongzhang efficacyofneoadjuvantchemotherapydoxandxeloxregimensforpatientswithresectablegastricorgastroesophagealjunctionadenocarcinoma AT xuefengzhao efficacyofneoadjuvantchemotherapydoxandxeloxregimensforpatientswithresectablegastricorgastroesophagealjunctionadenocarcinoma AT bibotan efficacyofneoadjuvantchemotherapydoxandxeloxregimensforpatientswithresectablegastricorgastroesophagealjunctionadenocarcinoma AT dongwang efficacyofneoadjuvantchemotherapydoxandxeloxregimensforpatientswithresectablegastricorgastroesophagealjunctionadenocarcinoma AT peigangyang efficacyofneoadjuvantchemotherapydoxandxeloxregimensforpatientswithresectablegastricorgastroesophagealjunctionadenocarcinoma |